[ad_1]
Agency
CITY OF MEXICO.- Before the international notification for defects in the active substance Valsartan, the Federal Commission for Protection against Health Risks (Cofepris) ordered not to market the product available to the company Zhejiang Huahai Pharmaceutical Co. Ltd. in China and recall drugs associated with this asset.
Valsartan is the major active ingredient in drugs used for the treatment of heart failure and antihypertensive. [19659002] It might also interest you: Attention! It circulates the drug 'duck & # 39; against hepatitis C
The products identified up to now containing Valsartan from the manufacturer Zhejiang Huahai Pharmaceutical Co. Ltd., are as follows: Diovalte, Vapispre, Vigisan, Avalraam, Menfhipress, Versalver, Vzar, Vagsar. These drugs are removed from the market.
According to data from the El Informador portal, Cofepris carries out the traceability of the raw material to determine the companies that use this ingredient in Mexico produced by the Chinese company for the preparation of drugs.
This notification has affected several countries, so that Cofepris, through its international cooperation programs, will join the corresponding sanitary control actions to avoid any risk for the population.
"If you have them, you can contact the laboratories that appear as the owners of the registry (…), to determine the return mechanism," says Cofepris.
Recommended patients who use the drugs with Valsartan mentioned above, do not stop the treatment and go to the doctor to get the prescription of an alternative drug that has the same function depending on the treatment that is made.
Doctors asked to review the treatments and substitute the drug for another with the same composition or the same therapeutic indication that is not in the withdrawal
Pharmacies indicated that before the presentation of a prescription with the active ingredient Valsartan, tell the patient to consult his doctor and not to stop the treatment.
"The Cofepris will monitor that it is not marketed The drugs mentioned above, will continue surveillance actions, monitoring the withdrawal of products that may be involved. withdrawal "Applied to drugs with Valsartan originating from Zhejiang Huahai Pharmaceutical Co. Ltd. in China," the agency said.
[ad_2]
Source link
